Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director · President & CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,627 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 418 · Balance 54,627 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 28 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,334 | $7.21 | $240,338.14 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| July 23, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · derivative · entry 8 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| July 23, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $32.10 | $1,069,989.30 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $32.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 23, 2019 Filed Jul 26, 2019 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-043289 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 23, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 23, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $32.69 | $1,089,655.77 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.02 to $33.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 23, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 22, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,334 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,334 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 22, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,334 | $33.38 | $1,112,688.92 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.07 to $33.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 22, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,334 | $7.21 | $240,338.14 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 21, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · derivative · entry 8 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 21, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $32.93 | $1,097,655.69 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.43 to $33.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 21, 2019 Filed May 23, 2019 23:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-032499 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| May 16, 2019 Filed May 18, 2019 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,383 | $31.37 | $419,824.71 |
DisclosureSEC source: 0001209191-19-031189 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,326 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.86 to $32.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · derivative · entry 11 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $41.01 | $1,366,986.33 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,709 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $40.24 to $42.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,334 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Underlying: Common Stock · 33,334 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,334 | $43.20 | $1,440,028.80 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,709 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $42.82 to $44.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,334 | $7.21 | $240,338.14 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock · Derivative | 33,333 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 33,333 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,882 | $42.39 | $376,507.98 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,709 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,333 | $42.32 | $1,410,652.56 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,591 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.87 to $42.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,333 | $7.21 | $240,330.93 |
DisclosureSEC source: 0001209191-19-012336 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 138,350 | $0.00 Strike: $36.51 | $0.00 |
DisclosureSEC source: 0001209191-18-063301 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,350 Underlying: Common Stock · 138,350 shares Expires 2026-12-13 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 68,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063301 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,591 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,326 | $38.25 | $586,219.50 |
DisclosureSEC source: 0001209191-18-059295 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,141 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 20,389 | $58.40 | $1,190,717.60 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,467 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 151,250 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · derivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,250 Underlying: Common Stock · 151,250 shares Expires 2025-12-14 F6 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F7 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F8 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 60,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,856 F3 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. Read SEC document |
| August 14, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 40,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · derivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| August 14, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 40,000 | $60.08 | $2,403,200.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,356 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $59.39 to $60.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 14, 2018 Filed Aug 17, 2018 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,000 | $10.69 | $427,600.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,356 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 27, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,333 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 43,333 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 27, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,333 | $47.39 | $2,053,550.87 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,356 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $45.63 to $49.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 27, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,333 | $10.69 | $463,229.77 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,333 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 43,333 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,333 | $49.36 | $2,138,916.88 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,356 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.59 to $51.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,333 | $10.69 | $463,229.77 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,334 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · derivative · entry 8 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,666 Underlying: Common Stock · 43,334 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,334 | $51.82 | $2,245,567.88 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,356 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $51.06 to $53.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,334 | $10.69 | $463,240.46 |
DisclosureSEC source: 0001209191-18-039717 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2019. Read SEC document |
| May 16, 2018 Filed May 18, 2018 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 12,791 | $83.39 | $1,066,641.49 |
DisclosureSEC source: 0001209191-18-031597 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,356 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.35 to $84.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,333 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · derivative · entry 10 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 43,333 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,333 | $82.86 | $3,590,572.38 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,147 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. F4 · price: This transaction was executed in multiple trades at prices ranging from $81.37 to $84.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,333 | $10.69 | $463,229.77 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
| May 02, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,333 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · derivative · entry 9 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,333 Underlying: Common Stock · 43,333 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
| May 02, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,333 | $85.63 | $3,710,604.79 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,147 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.96 to $86.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 02, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,333 | $10.69 | $463,229.77 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
| May 01, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 43,334 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · derivative · entry 8 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,666 Underlying: Common Stock · 43,334 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.